

MONDAY, NOVEMBER 24, 2008

TOPIC: **Current Legal Issues in the Biopharmaceutical Industry**

SPEAKERS: **Joseph R. Robinson**, Principal, Darby & Darby P.C.
Phoebe A. Wilkinson, Partner, Chadbourne & Parke LLP

For this program, we will hear from two legal experts on a mixed bag of hot legal topics affecting the biopharmaceutical industry. They will provide an overview of:

- U.S. litigation trends
- Patent litigation such as Hatch-Waxman reverse payment settlements
- The growing risk of product liability litigation in other countries – what to consider and how to prepare
- Alternatives to litigation, for example, re-exam, interference, arbitration, mediation, etc.
- How to deal with a patent portfolio during a severe, prolonged economic downturn, including what to prosecute, licensing, litigation, etc.

Joseph Robinson specializes in patent litigation, counseling and procurement in biotechnical, pharmaceutical, chemical and mechanical technologies. His practice also encompasses trademark procurement, counseling and litigation. He is particularly involved with international and multinational matters and is the co-principal in charge of Darby & Darby's Japanese Practice group. He has extensive experience in litigating patent matters and counseling in areas such as recombinant molecular biology, pharmaceuticals, enzyme technology, electrochemistry, food chemistry and organic chemistry. He has procured patents covering inventions in a wide range of fields, and actively participated in the negotiations and drafting of license agreements in the biotechnology and pharmaceutical areas.

Phoebe Wilkinson's areas of expertise include class action defense, product liability and commercial litigation. She has served as counsel to pharmaceutical manufacturers in over 1,500 high profile product liability litigations filed in state and federal courts throughout the U.S. She has also served as counsel on U.S. regulatory, risk management and product liability matters. Moreover, she has represented major international companies in their product liability litigation. She has been extensively published on issues ranging from personal injury product liability claims to the merits of pro bono programs. She is also a frequent speaker on topics such as pharmaceutical litigation and class actions.